SCHEMBL23770648

SCHEMBL23770648

Cc1cccc(C)c1-c1nc(NSc2cccc(N3CCCC(C(=O)O)C3)n2)ccc1Cl

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPBAR1 Q8TDU6 2/20 0.41
P2RX7 Q99572 1/20 0.39
KMT2A Q03164 3/20 0.39
KDM4E B2RXH2 1/20 0.39
MEN1 O00255 1/20 0.39
ALDH1A1 P00352 1/20 0.39
HSD17B10 Q99714 1/20 0.39
HSD11B1 P28845 1/20 0.37
NOTUM Q6P988 3/20 0.37
TSHR P16473 2/20 0.36
SLC6A1 P30531 2/20 0.35
MAPT P10636 2/20 0.35
IDH2 P48735 1/20 0.35
POLB P06746 1/20 0.34
MAP3K5 Q99683 1/20 0.34
LMNA P02545 1/20 0.34
XBP1 P17861 1/20 0.34
HTT P42858 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
ALK Q9UM73 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23770668 0.92 GPBAR1 (0.40) GPBAR1P2RX7KMT2AKDM4EMEN1
SCHEMBL23770656 0.85 P2RX7 (0.39) GPBAR1P2RX7KMT2AKDM4EMEN1
SCHEMBL23770813 0.85 ITGB2 (0.40) GPBAR1P2RX7KMT2AKDM4EMEN1
SCHEMBL23770837 0.84 SMO (0.34) KMT2AKDM4EMEN1ALDH1A1TSHR
SCHEMBL23770485 0.84 P2RX7 (0.38) GPBAR1P2RX7KMT2AKDM4EMEN1
SCHEMBL23770785 0.83 LMNA (0.43) KMT2AKDM4EMEN1ALDH1A1HSD17B10
SCHEMBL23770844 0.82 PTPN11 (0.33)
SCHEMBL23770488 0.81 ITGB2 (0.40) GPBAR1KMT2AKDM4EMEN1ALDH1A1
SCHEMBL19970116 0.81 DGAT1 (0.35)
SCHEMBL23770659 0.80 PTPN11 (0.36)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3504194-B1 N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE NOVARTIS AG (CH) 2021-08-18 EP disclosed